Certified Advisory Corp’s Nektar Therapeutics NKTR Stock Holding History

Certified Advisory Corp’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-49	Closed	-$15K	–	541
2021 Q1	$15K	Buy	+49	New	+$15.3K	﹤0.01%	545
2020 Q2	$29K	Hold	82	–	–	0.01%	384
2020 Q1	$22K	Buy	82 +35	+74%	+$10.8K	0.01%	396
2019 Q4	$15K	Hold	47	–	–	﹤0.01%	531
2019 Q3	$13K	Sell	47 -75	-61%	-$27.5K	﹤0.01%	551
2019 Q2	$65K	Sell	122 -3	-2%	-$1.5K	0.02%	280
2019 Q1	$63K	Sell	125 -78	-38%	-$46.2K	0.03%	271
2018 Q4	$100K	Sell	203 -3	-1%	-$1.81K	0.05%	197
2018 Q3	$189K	Buy	206 +6	+3%	+$5.12K	0.09%	156
2018 Q2	$146K	Buy	200 +8	+4%	+$9.22K	0.08%	159
2018 Q1	$306K	Buy	192 +26	+16%	+$33.5K	0.18%	113
2017 Q4	$148K	Buy	+166	New	+$98.2K	0.11%	135

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Certified Advisory Corp's NKTR Position: Q2 2021 in Review

Certified Advisory Corp sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 49 shares — an estimated $15K sold.

Certified Advisory Corp first reported a position in NKTR in Q4 2017 and held it in 12 quarters. The position peaked at $306K in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

Certified Advisory Corp reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
Certified Advisory Corp sold 49 Nektar Therapeutics shares in Q2 2021, an estimated $15K.
Certified Advisory Corp first reported a position in Nektar Therapeutics in Q4 2017 and held it in 12 quarters.
Certified Advisory Corp's Nektar Therapeutics position peaked at $306K in Q1 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Certified Advisory Corp's 13F filing for Q2 2021, filed 16 Aug 2021.